Showing results (481-490 of 553) with videos related to
Sort By:
Pageof 56
Drugs in Context|April 4, 2022
Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in AsiaWai Kwong Cheong, Alson Wai Ming Chan, Chin Chwen Ch'ng, et al.Drugs in Context|January 28, 2021
Current therapeutic strategies in connective tissue disease-related interstitial lung disease: introduction to the special issueGian Luca Erre, Arduino Aleksander MangoniDrugs in Context|March 1, 2019
Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challengesShinichi Makita, Katsuaki Imaizumi, Saiko Kurosawa, et al.Drugs in Context|August 13, 2019
New uses and formulations of glucagon for hypoglycaemiaPilar I Beato-Víbora, Francisco J Arroyo-DíezDrugs in Context|July 14, 2018
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implicationsNicola Personeni, Tiziana Pressiani, Armando Santoro, et al.Drugs in Context|August 18, 2018
Advances in the use of PARP inhibitor therapy for breast cancerKelly E McCann, Sara A HurvitzDrugs in Context|September 1, 2015
Alpha-2 receptor agonists for the treatment of posttraumatic stress disorderMolly R Belkin, Thomas L SchwartzDrugs in Context|November 24, 2017
Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patientS Morelli, E PuxedduDrugs in Context|November 24, 2017
Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapiesSabrina Rossi, Alessandra Cassano, Antonia Strippoli, et al.Drugs in Context|February 16, 2018
Practical outpatient pharmacotherapy for alcohol use disorderYoungjung Kim, Laura M Hack, Elizabeth S Ahn, et al.Pageof 56